Enrico N De Toni

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Topics

Liver Metastases

Radiofrequency Ablation

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Bruno Sangro, Peter R Galle, Robin Kate Kelley, Chaiyut Charoentum, Enrico N De Toni, Yurii Ostapenko, Jeong Heo, Ann-Lii Cheng, Andrea Wilson Woods, Charu Gupta, Jayne Abraham, Carrie L McCoy, Nikunj Patel, Alejandra Negro, Arndt Vogel, Ghassan K Abou-Alfa
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
Enrico N De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Alimentary pharmacology & therapeutics (2024)
Enrico N De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Alimentary pharmacology & therapeutics 59 (11) (2024)
Bruno Sangro, Peter R Galle, Robin Kate Kelley, Chaiyut Charoentum, Enrico N De Toni, Yurii Ostapenko, Jeong Heo, Ann-Lii Cheng, Andrea Wilson Woods, Charu Gupta, Jayne Abraham, Carrie L McCoy, Nikunj Patel, Alejandra Negro, Arndt Vogel, Ghassan K Abou-Alfa
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
Enrico N De Toni, Julia Mayerle, Bettina Oehrle, Max Seidensticker, Lorenza Rimassa, Alexander Philipp, Daniel Roessler, Najib Ben Khaled
Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Alimentary pharmacology & therapeutics 59 (11) (2024)
Bruno Sangro, Peter R Galle, Robin Kate Kelley, Chaiyut Charoentum, Enrico N De Toni, Yurii Ostapenko, Jeong Heo, Ann-Lii Cheng, Andrea Wilson Woods, Charu Gupta, Jayne Abraham, Carrie L McCoy, Nikunj Patel, Alejandra Negro, Arndt Vogel, Ghassan K Abou-Alfa
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Bruno Sangro, Peter R Galle, Robin Kate Kelley, Chaiyut Charoentum, Enrico N De Toni, Yurii Ostapenko, Jeong Heo, Ann-Lii Cheng, Andrea Wilson Woods, Charu Gupta, Jayne Abraham, Carrie L McCoy, Nikunj Patel, Alejandra Negro, Arndt Vogel, Ghassan K Abou-Alfa
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (23) (2024)
Teerha Piratvisuth, Jin-Lin Hou, Tawesak Tanwandee, Thomas Berg, Arndt Vogel, Jörg Trojan, Enrico N De Toni, Masatoshi Kudo, Anja Eiblmaier, Hanns-Georg Klein, Johannes Kolja Hegel, Kairat Madin, Konstantin Kroeniger, Ashish Sharma, Henry Lik Yuen Chan
Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies. Hepatology communications 7 (11) (2023)
Friedrich Sinner, Matthias Pinter, Bernhard Scheiner, Thomas Jens Ettrich, Niklas Sturm, Maria Angeles Gonzalez-Carmona, Oliver Waidmann, Fabian Finkelmeier, Vera Himmelsbach, Enrico N De Toni, Najib Ben Khaled, Raphael Mohr, Thorben Wilhelm Fründt, Fabian Kütting, Florian van Boemmel, Sabine Lieb, Sebastian Krug, Dominic Bettinger, Michael Schultheiß, Leonie S Jochheim, Jan Best, Christian Müller, Verena Keitel, Marino Venerito
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers 14 (23) (2022)
Friedrich Sinner, Matthias Pinter, Bernhard Scheiner, Thomas Jens Ettrich, Niklas Sturm, Maria Angeles Gonzalez-Carmona, Oliver Waidmann, Fabian Finkelmeier, Vera Himmelsbach, Enrico N De Toni, Najib Ben Khaled, Raphael Mohr, Thorben Wilhelm Fründt, Fabian Kütting, Florian van Boemmel, Sabine Lieb, Sebastian Krug, Dominic Bettinger, Michael Schultheiß, Leonie S Jochheim, Jan Best, Christian Müller, Verena Keitel, Marino Venerito
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers 14 (23) (2022)
Paula Sagmeister, Jimmy Daza, Andrea Ofner, Andreas Ziesch, Liangtao Ye, Najib Ben Khaled, Matthias Ebert, Julia Mayerle, Andreas Teufel, Enrico N De Toni, Stefan Munker
Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis. Journal of hepatocellular carcinoma 9 (2022)
Najib Ben Khaled, Max Seidensticker, Jens Ricke, Julia Mayerle, Bettina Oehrle, Daniel Rössler, Daniel Teupser, Ursula Ehmer, Michael Bitzer, Dirk Waldschmidt, Martin Fuchs, Philipp A Reuken, Christian M Lange, Henning Wege, Arne Kandulski, Alexander Dechêne, Marino Venerito, Marie-Luise Berres, Tom Luedde, Ilja Kubisch, Florian P Reiter, Enrico N De Toni
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol. Future oncology (London, England) 18 (12) (2022)
Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A Widholz, Ignazio Piseddu, Simon Sirtl, Julia Schneider, Stefan Munker, Ujjwal Mukund Mahajan, Juan José Montero, Joscha Griger, Julia Mayerle, Florian P Reiter, Enrico N De Toni
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Cancers 14 (21) (2022)
Friedrich Sinner, Matthias Pinter, Bernhard Scheiner, Thomas Jens Ettrich, Niklas Sturm, Maria Angeles Gonzalez-Carmona, Oliver Waidmann, Fabian Finkelmeier, Vera Himmelsbach, Enrico N De Toni, Najib Ben Khaled, Raphael Mohr, Thorben Wilhelm Fründt, Fabian Kütting, Florian van Boemmel, Sabine Lieb, Sebastian Krug, Dominic Bettinger, Michael Schultheiß, Leonie S Jochheim, Jan Best, Christian Müller, Verena Keitel, Marino Venerito
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience. Cancers 14 (23) (2022)
Najib Ben Khaled, Daniel Roessler, Florian P Reiter, Max Seidensticker, Markus Guba, Enrico N De Toni
Extending the Use of Atezolizumab and Bevacizumab to a Liver Transplant Recipient: Need for a Posttransplant Registry. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 27 (6) (2021)
Enrico N De Toni, Daniel Roessler
Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma. Gut 69 (11) (2020)
Stephan Spahn, Daniel Roessler, Radu Pompilia, Gisela Gabernet, Beryl Primrose Gladstone, Marius Horger, Saskia Biskup, Magdalena Feldhahn, Sven Nahnsen, Franz J Hilke, Bernhard Scheiner, Jean-François Dufour, Enrico N De Toni, Matthias Pinter, Nisar P Malek, Michael Bitzer
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers 12 (12) (2020)
Enrico N De Toni
Immune checkpoint inhibitors: use them early, combined and instead of TACE? Gut 69 (10) (2019)
Enrico N De Toni, Anne Schlesinger-Raab, Martin Fuchs, Wolfgang Schepp, Ursula Ehmer, Fabian Geisler, Jens Ricke, Philipp Paprottka, Helmut Friess, Jens Werner, Alexander L Gerbes, Julia Mayerle, Jutta Engel
Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 69 (1) (2019)